For the Quarter Ending March 2026
Apixaban Prices in North America
- In United States, the Apixaban Price Index rose quarter-over-quarter in Q1 2026, driven by surging aniline feedstock costs.
- During March 2026, the Producer Price Index increased 4.0% year-over-year, while the Consumer Price Index rose 3.3%.
- Retail sales grew 4.0% year-over-year in March 2026, supported by a stable 4.3% unemployment rate.
- Industrial production grew 0.7% year-over-year in March 2026, and the Manufacturing Index expanded during the same period.
- The consumer confidence index reached 91.8 in March 2026, supporting a stable Apixaban Demand Outlook.
- Crude oil prices surged in March 2026, and natural gas spot prices spiked during January 2026.
- Import costs for aniline feedstocks increased across regions in Q1 2026 due to severe logistics disruptions.
- Generic Apixaban supply availability improved significantly in Q1 2026, and supply chains stabilized during January 2026.
- The Apixaban Price Forecast reflected upward pressure in Q1 2026 as aniline production faced severe disruptions.
Why did the price of Apixaban change in March 2026 in North America?
- Aniline feedstock costs surged globally in Q1 2026 due to escalating Middle East geopolitical tensions.
- Global product export flows through the Strait of Hormuz halted almost completely in March 2026.
- The Apixaban Production Cost Trend increased in Q1 2026 as crude-linked cost support strengthened significantly.
Apixaban Prices in APAC
- In China, the Apixaban Price Index rose quarter-over-quarter in Q1 2026, driven by escalating precursor expenses.
- The Consumer Price Index increased 1.0% in March 2026, reflecting a stable Apixaban Demand Outlook.
- The Producer Price Index grew 0.5% in March 2026, reflecting an upward Apixaban Production Cost Trend.
- The manufacturing index expanded in March 2026, confirming robust domestic production capabilities for Apixaban synthesis.
- Industrial production grew 5.7% in March 2026, ensuring steady availability of chemical reagents for Apixaban.
- Retail sales grew 1.7% in March 2026, demonstrating softer consumer spending impacting outpatient Apixaban purchases.
- The urban unemployment rate reached 5.4% in March 2026, reducing disposable income for premium Apixaban.
- Consumer confidence dropped to 91.6 in February 2026, reducing the rate of new Apixaban prescriptions.
- The Apixaban Price Forecast reflected upward pressure as downstream procurement activity intensified in March 2026.
- Naphtha feedstock costs and upstream benzene expenses escalated significantly for chemical manufacturers in Q1 2026.
Why did the price of Apixaban change in March 2026 in APAC?
- Aniline feedstock costs for Apixaban synthesis surged amid unexpected regional production adjustments in Q1 2026.
- Import costs for Apixaban chemical precursors increased due to severe maritime disruptions in Q1 2026.
- Market availability of Apixaban base chemicals remained constrained due to supply disruptions in Q1 2026.
Apixaban Prices in Europe
- In Germany, the Apixaban Price Index rose quarter-over-quarter in Q1 2026, driven by surging upstream feedstock costs.
- Consumer inflation reached 2.7 percent while producer prices fell 0.2 percent in March 2026, impacting the Apixaban Production Cost Trend.
- The Manufacturing Index expanded in March 2026, despite stagnant 0.0 percent industrial production during February 2026, stabilizing Apixaban supply.
- Retail sales grew 0.7 percent and unemployment remained 4.2 percent in February 2026, supporting a positive Apixaban Demand Outlook.
- Negative consumer confidence at -24.7 in March 2026 drove cautious spending, negatively impacting the Apixaban Price Forecast.
- European benzene feedstock costs for pharmaceutical synthesis surged in March 2026, elevating Apixaban production expenses significantly.
- German pharmaceutical manufacturing output contracted sharply in January 2026, reflecting weakened demand across sectors including Apixaban.
- Apixaban export shipments from Germany maintained a diversified sourcing base with multiple active suppliers in February 2026.
Why did the price of Apixaban change in March 2026 in Europe?
- European benzene feedstock costs surged in March 2026, directly increasing Apixaban active ingredient manufacturing expenses.
- Natural gas benchmark prices spiked in March 2026, elevating utility costs for German Apixaban production.
- Regional supply of aniline tightened in Q1 2026, creating upward cost pressure on Apixaban synthesis.
For the Quarter Ending December 2025
Apixaban Prices in North America
- In United States, the Apixaban Price Index rose quarter-over-quarter in Q4 2025, driven by increasing production costs.
- Apixaban production costs faced upward pressure from a 2.7% year-over-year CPI increase in December 2025.
- Rising input costs for manufacturers, indicated by a 3.0% year-over-year PPI increase in November 2025, impacted Apixaban.
- The pharmaceutical sector's market performance strengthened in Q4 2025, indicating cautious optimism for Apixaban demand.
- A strong labor market, with a 4.4% unemployment rate in December 2025, supported patient access and Apixaban affordability.
- Industrial production increased by 2.0% year-over-year in December 2025, providing a supportive economic backdrop.
- Capital constraints and higher financing costs intensified for chemical firms in Q4 2025, impacting Apixaban investments.
- Henry Hub natural gas prices fluctuated in Q4 2025, strengthening before weakening significantly by December.
- The Apixaban price forecast indicates continued upward pressure from sustained cost increases and stable demand.
Why did the price of Apixaban change in December 2025 in North America?
- Rising input costs, evidenced by a 2.7% CPI increase in December 2025, pressured Apixaban production.
- A 3.0% PPI increase in November 2025 indicated higher intermediate chemical costs, impacting Apixaban manufacturing.
- Strengthening pharmaceutical market performance in Q4 2025 and a strong labor market supported Apixaban demand.
Apixaban Prices in APAC
- In China, the Apixaban Price Index fell quarter-over-quarter in Q4 2025, influenced by weak consumer demand.
- Apixaban production costs declined in Q4 2025 due to persistent overcapacity in chemical building blocks.
- Apixaban demand outlook remained stable in Q4 2025, supported by robust pharmaceutical market growth.
- The Apixaban Price Index faced downward pressure in December 2025 as producer prices declined by 1.9%.
- Industrial production expanded by 5.2% year-over-year in December 2025, supporting stable Apixaban supply.
- Weak retail sales growth of 0.9% year-over-year in December 2025 indicated subdued consumer spending.
- The Manufacturing Index expanded in December 2025, signaling growth in the manufacturing sector.
- A moderate unemployment rate of 5.1% in December 2025 supported patient affordability for Apixaban.
- Global oil stocks built in December 2025, contributing to stable energy feedstock costs.
Why did the price of Apixaban change in December 2025 in APAC?
- Producer prices declined by 1.9% year-over-year in December 2025, reducing Apixaban manufacturing costs.
- Weak consumer demand, with CPI at 0.8% year-over-year in December 2025, limited Apixaban pricing power.
- Persistent overcapacity in chemical building blocks in China throughout 2025 exerted downward pressure on feedstock.
Apixaban Prices in Europe
- In Germany, Apixaban Price Index faced mixed pressures in Q4 2025, influenced by a contracting Manufacturing Index.
- Production costs for Apixaban faced upward pressure in Q4 2025 from elevated energy, raw materials, and 1.8% CPI.
- However, the producer price index (PPI) declined 2.5% year-over-year in December 2025, easing industrial input costs.
- Demand for Apixaban was supported by a strengthened German pharmaceutical market in 2025 for high-value therapies.
- Overall economic sentiment remained stable in November 2025, with retail sales growing 1.1% year-over-year.
- A 6.2% unemployment rate in December 2025 and negative consumer confidence strained healthcare budgets.
- Industrial production grew 0.8% year-over-year in October 2025, supporting stable supply chains.
- Apixaban Price Forecast suggests continued influence from elevated energy costs and resilient pharmaceutical demand.
Why did the price of Apixaban change in December 2025 in Europe?
- Elevated energy costs in Q4 2025 pressured production, alongside 1.8% CPI, despite a 2.5% PPI decline.
- Strong pharmaceutical demand in 2025 supported prices, despite a contracting Manufacturing Index.
- Broader economic weakness, with 6.2% unemployment in December 2025, strained healthcare funding.
For the Quarter Ending September 2025
Apixaban Prices in North America
- In the United States, the Apixaban Price Index rose in Q3 2025, reflecting strengthening production costs and robust healthcare spending.
- Apixaban production costs increased in Q3 2025, driven by a 2.6% PPI rise in August 2025 and strengthened chemical input costs.
- Demand for Apixaban was supported by strengthening US pharmaceutical market sentiment and accelerating national healthcare spending.
- Industrial electricity costs strengthened in September 2025, contributing to higher Apixaban manufacturing expenses.
- US chemical production contracted in Q3 2025, reflecting weak 0.1% industrial production growth in September 2025.
- US chemical manufacturing inventories tightened in Q3 2025 due to accelerating destocking, impacting Apixaban supply.
- Retail sales increased 5.42% in September 2025, indicating strong consumer spending, contrasting with declining consumer confidence (94.2).
- The unemployment rate was 4.3% in September 2025, posing potential barriers to healthcare access and Apixaban affordability.
Why did the price of Apixaban change in September 2025 in North America?
- Production costs increased due to a 3.0% CPI rise in September 2025 and strengthened general chemical input costs.
- Strong US pharmaceutical market sentiment and accelerating national healthcare spending boosted Apixaban demand.
- Tightening chemical manufacturing inventories and weakened pharmaceutical exports influenced Apixaban supply.
Apixaban Prices in Europe
- In Germany, the Apixaban Price Index fell quarter-over-quarter in Q3 2025, influenced by declining producer prices for the pharmaceutical industry.
- Apixaban production costs declined in Q3 2025, supported by a -1.7% year-over-year decrease in producer prices in September 2025.
- Easing naphtha feedstock prices and declining European natural gas prices in Q3 2025 contributed to lower Apixaban production expenses.
- Apixaban demand remained steady in Q3 2025, supported by firming pharmaceutical output and a 3.9% unemployment rate in September 2025.
- Moderate inflation, with CPI at 2.4% year-over-year in September 2025, increased operational costs for Apixaban manufacturers.
- Weakening consumer confidence (-23.6 in September 2025) indirectly influenced healthcare spending, despite modest retail sales growth.
- Chemical industry inventories tightened in Q3 2025 due to accelerated destocking activities, impacting supply dynamics.
The manufacturing index was contracting in September 2025, reflecting a -1.0% year-over-year decline in industrial production.
Why did the price of Apixaban change in September 2025 in Europe?
- Producer prices for the chemical and pharmaceutical industry declined in Q3 2025, reducing input costs for Apixaban.
- Naphtha feedstock prices eased in Q3 2025, alongside declining European natural gas prices, lowering energy expenses.
- Overall chemical demand weakened in Q3 2025, contributing to downward price pressure despite firming pharmaceutical output.
Apixaban Prices in APAC
- In China, the Apixaban Price Index fell quarter-over-quarter in Q3 2025, influenced by deflationary pressures and market oversupply conditions.
- Apixaban production costs declined in September 2025, as producer prices for raw chemical materials decreased year-on-year by -2.3%.
- Persistent global oversupply and increased domestic capacity in Q3 2025 exerted significant downward pressure on the Apixaban Price Index.
- Demand for Apixaban intermediates showed strong growth in Q3 2025, supported by rising pharmaceutical R&D activities in China.
- Weakened industrial electricity prices in some major Chinese hubs in Q3 2025 contributed to lower Apixaban manufacturing expenses.
- China's Manufacturing Index was contracting in September 2025, indirectly impacting overall economic sentiment for the chemical sector.
- The Apixaban Price Forecast suggests continued moderation, given the -0.3% year-on-year CPI in September 2025.
- Apixaban demand outlook remained stable in Q3 2025, supported by a 5.2% unemployment rate in September 2025.
Why did the price of Apixaban change in September 2025 in APAC?
- Producer prices for raw chemical materials declined by -2.3% year-on-year in September 2025, reducing Apixaban production costs.
- China's chemical industry experienced oversupply and increased capacity in Q3 2025, exerting downward pressure on prices.
- Deflationary pressures, with CPI at -0.3% year-on-year in September 2025, contributed to a falling Apixaban Price Index.
For the Quarter Ending December 2022
North America
- The Apixaban API market in North America displayed an erratic pattern in the fourth quarter of 2022. Prices were anticipated to increase in the second month of Q4 2022 as a result of rising end-user sector demand and other logistical difficulties. Zero covid rules were implemented, causing trade to be hampered and halted shipments, further influencing the market.
- Despite greater production costs driven by rising energy prices, the market remained competitive. However, later in December, due to domestic retailers having an adequate supply on hand, Apixaban API prices decreased. By the end of Q4 2022, prices were recorded to drop with values accessed at USD 3252200/MT CFR New York.
APAC
The Asia Pacific Apixaban API market saw high volatility in the fourth quarter of 2022. The Apixaban price rose through the second quarter month due to increased end-user sector demand, several logistical challenges, and rising inflation. The prices at the conclusion of the second month of the fourth quarter were USD 2480020/MT FOB Shanghai. The market remained competitive due to increasing production costs brought on by rising energy prices and increased domestic output to meet demand from domestic and foreign markets. The tight zero covid policies and frequent lockdowns in the Chinese regions have impacted the market. By the end of December, domestic retailers had enough inventories, causing prices to drop to USD 2466500/MT FOB Shanghai. Additionally, other restrictions, including the removal of the zero covid policy, had an impact on the market.
Europe
Market sentiments for Apixaban API in Europe showed erratic volatility in the fourth quarter of 2022. Prices started to rise at the beginning of Q4 2022 and continued to rise through the second month of the quarter as a result of rising end-user sector demand and other logistical difficulties. Zero covid regulations were put into place, which hindered trade and stopped shipments, which benefitted the European Apixaban market. The market remained competitive despite higher manufacturing costs brought on by rising energy prices. Apixaban API prices did drop later in December, though, as domestic dealers had a sufficient supply on hand. The market remained low in December as a result of loosening policy and weak downstream demand. The figures were retrieved at USD 2855200/MT toward the conclusion of Q4.
